Omega Therapeutics (OMGA)

• Market cap: $46.3M
• 1 day: 3.02%
• 5 days: -12.70%
• 1 month: 5.91%
• 3 months: -38.91%
• 6 months: -61.96%
• Year to date: -71.82%
• 1 year: -62.80%
• 5 years: -94.77%
• 10 years: -94.77%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.

Employees: 94

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more call options, than puts

Call options by funds: $33K | Put options by funds: $11K

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

4.24% less ownership

Funds ownership: 91.79% [Q2] → 87.55% (-4.24%) [Q3]

21% less funds holding

Funds holding: 67 [Q2] → 53 (-14) [Q3]

44% less capital invested

Capital invested by funds: $105M [Q2] → $58.9M (-$45.9M) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 14

67% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 21

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 378% upside
• Avg. target: $4 378% upside
• High target: $4 378% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Edward Tenthoff 23% 1-year accuracy 10 / 43 met price target

378% upside $4

Overweight Maintained

15 Nov 2024